预约演示
更新于：2026-07-18
Dimenhydrinate
茶苯海明
更新于：2026-07-18
概要
基本信息
简介苯海拉明 (DPH) 是一种抗组胺剂和镇静剂，主要用于治疗过敏、失眠和普通感冒症状。 它可以口服、静脉注射、肌肉注射或涂在皮肤上。 最大效果通常在服药后两小时左右出现，效果可持续长达七小时。 它是第一代 H1 抗组胺剂和乙醇胺，通过阻断组胺的某些作用发挥作用，从而产生抗组胺剂和镇静作用。 苯海拉明也是一种有效的抗胆碱能药。 常见的副作用包括嗜睡、协调性差和胃部不适。 |
药物类型 小分子化药 |
别名 (O-benzhydryl(dimethylamino)ethanol) 8-chlorotheophyllinate、Benzhydryl-β-dimethylaminoethylether 8-chlorotheophylline、Dimenhydrinate (JP17/USP/INN) + [11] |
作用方式 拮抗剂 |
作用机制 H1 receptor拮抗剂(组胺H1受体拮抗剂) |
非在研适应症- |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H28ClN5O3 |
InChIKeyNFLLKCVHYJRNRH-UHFFFAOYSA-N |
CAS号523-87-5 |
关联
20
项与 茶苯海明 相关的临床试验CTIS2025-523948-12-00
Bioequivalence of Cinnarizine/Dimenhydrinate 20 mg/40 mg Tablets in Healthy Participants Under Fed Conditions.
CTIS2024-515170-27-00
Evaluation of bioequivalence of two products containing 50 mg dimenhydrinate: Dimenhydrinate 50 mg (Test) vs. Vomex A 50 mg Lösung zum Einnehmen im Beutel (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers
NCT06395064
The Effect of Dimenhydrinate on Postoperative Nausea and Vomiting After Abdominal Hysterectomy: Randomized-controlled Trial
100 项与 茶苯海明 相关的临床结果
登录后查看更多信息
100 项与 茶苯海明 相关的转化医学
登录后查看更多信息
100 项与 茶苯海明 相关的专利（医药）
登录后查看更多信息
666
项与 茶苯海明 相关的文献（医药）2026-09-01JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
A twin enrichment method based on dual-template molecularly imprinted polymer and dispersive liquid-liquid microextraction for simultaneous determination of two COVID-19 medicines in biological fluids
Article
作者: Zareiyan, Faraneh ; Khajehsharifi, Habibollah ; Rajabi, Hamid Reza
This study introduces a twin enrichment strategy based on dual-template molecularly imprinted polymer-assisted solid-phase microextraction coupled with dispersive liquid-liquid microextraction (MISPE-DLLME) for the simultaneous extraction and determination of favipiravir and remdesivir in biological matrices (blood and urine), followed by high-performance liquid chromatography with ultraviolet detection (HPLC-UV) analysis. The dual-template molecularly imprinted polymer (DT-MIP) was synthesized via precipitation polymerization and comprehensively characterized using Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), field-emission scanning electron microscopy (FESEM), Brunauer-Emmett-Teller (BET) surface area analysis, simultaneous thermal analysis (STA), and X-ray diffraction (XRD). Under optimized conditions, including pH 2.00 ± 0.1, 10.0 mg of MIP, 200 ± 5 μL of 1-dodecanol, 500 ± 10 μL of methanol, and an extraction time of 10.0 ± 0.5 min, the method afforded high recoveries of 103-110% with relative standard deviations (RSDs) below 5% (n = 3). The method showed excellent sensitivity, with limits of detection of 1.0 ng/mL for favipiravir and 0.40 ng/mL for remdesivir and limits of quantification of 3.3 ng/mL and 1.3 ng/mL, respectively. Selectivity was evaluated against ten structurally related drugs (ibuprofen, gemfibrozil, paracetamol, diazepam, clobazam, methocarbamol, theophylline, naproxen, dimenhydrinate, and cinnarizine) at various concentration ratios, and the DT-MIP displayed superior recognition performance compared with the corresponding non-imprinted polymer (NIP). Analysis of clinical samples yielded acceptable recoveries and precision, confirming the reliability of the proposed method and its potential applicability in therapeutic drug monitoring of COVID-19 antivirals.
2026-07-01VETERINARY ANAESTHESIA AND ANALGESIA
Effectiveness of dimenhydrinate and maropitant in preventing preoperative emesis and nausea in healthy dogs sedated with hydromorphone and dexmedetomidine: a randomized, blinded trial
Article
作者: Shin, Chi W ; Ambros, Barbara
OBJECTIVE:
To determine the antinausea and antiemetic effects of dimenhydrinate and maropitant in dogs when administered 60 minutes before hydromorphone and dexmedetomidine.
STUDY DESIGN:
Prospective, randomized, blinded, placebo-controlled clinical trial.
ANIMALS:
A total of 87 healthy client-owned dogs undergoing ovariectomy/castration.
METHODS:
Dogs were randomly assigned to be administered maropitant (1 mg kg-1; group M) subcutaneously (SC), dimenhydrinate (4 mg kg-1; group D) intramuscularly (IM), or 0.9% NaCl (0.1 mL kg-1; group C) SC 60 minutes before anesthetic premedication with hydromorphone (0.1 mg kg-1) and dexmedetomidine (5-15 μg kg-1) IM. Incidences of discomfort after injection of the treatment drug, nausea (ptyalism, lip licking, and swallowing), and vomiting/retching were documented. Scores for nausea and sedation were assigned immediately before premedication and for 20 minutes after premedication. Data were analyzed using Fisher's Exact test and Kruskal-Wallis test, with statistical significance set at p< 0.05.
RESULTS:
Discomfort to injection was significantly higher in group M (20/31, 64.5%) than in groups D (6/28, 21.4%) and C (2/28, 7.1%) (p< 0.0001). Incidence of nausea was not significantly different between treatment groups [group M; 23/31 (74.2%) versus group D; 27/28 (96%) versus group C; 23/28 (82.1%), p= 0.050]. The incidence of vomiting/retching was significantly lower in group M (0/31, 0%) compared to groups D (15/28, 53.6%) and C (9/28, 32.1%) (p< 0.0001).
CONCLUSIONS AND CLINICAL RELEVANCE:
Dimenhydrinate produced no measurable antinausea and antiemetic effect when administered 60 minutes before hydromorphone and dexmedetomidine. Maropitant SC prevented hydromorphone-induced emesis but was ineffective in reducing nausea.
2026-05-04Expert Opinion On Drug Safety
Potential drugs for reducing the occurrence of immune checkpoint inhibitor-induced interstitial lung disease: an exploratory study using the JADER and FAERS databases
Article
作者: Koseki, Takenao ; Kondo, Masashi ; Hatano, Masakazu ; Utsunomiya, Ayaka ; Yamada, Shigeki ; Imaizumi, Kazuyoshi
BACKGROUND:
Immune checkpoint inhibitors (ICIs) play a central role in cancer immunotherapy. However, the occurrence of immune-related adverse events, especially ICI-induced interstitial lung disease (ICI-ILD), is life-threatening and affects the effectiveness of ICI treatment. This study aimed to explore potential drugs to mitigate ICI-ILD occurrence using data from the Japanese Adverse Drug Event Report (JADER) and the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS [JAPIC AERS]).
RESEARCH DESIGN AND METHODS:
We investigated concomitant drugs that reduce ILD associated with four ICIs - nivolumab, pembrolizumab, atezolizumab, and durvalumab - across the JADER and FAERS databases. Subsequently, the identified common concomitant drugs that reduce the occurrence of ICI-ILD were detected and analyzed.
RESULTS:
We found omega-3 fatty acids, loperamide, and amlodipine as common concomitant drugs that reduced ICI-ILD occurrence in both the JADER and FAERS databases. Omega-3 fatty acids reportedly have many effects in animal models of drug-induced ILD, including their association with ILD in humans and anti-inflammatory effects against ICI-ILD. However, loperamide and amlodipine reportedly have minimal effects against ILD, thereby necessitating further evaluation.
CONCLUSION:
Omega-3 fatty acids have emerged as potential agents for reducing ICI-ILD occurrence, as evidenced by findings from two different pharmacovigilance databases.
16
项与 茶苯海明 相关的新闻（医药）2026-04-10
2026-03-03
2026-01-02
100 项与 茶苯海明 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 头晕 | 日本 | 1952-01-01 | |
| 恶心和呕吐 | 日本 | 1952-01-01 | |
| 术后恶心呕吐 | 日本 | 1952-01-01 | |
| 湿疹 | 日本 | 1951-09-11 | |
| 昆虫咬伤和螫伤 | 日本 | 1951-09-11 | |
| 瘙痒 | 日本 | 1951-09-11 | |
| 荨麻疹 | 日本 | 1951-09-11 | |
| 晕动病 | 中国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用